| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Executive VP and CLO | Executive VP and CLO
1 company
Boulding Mark Elliott serves as an Executive VP and CLO at PTCT. Across recent SEC filings that breaks down to 0 buys and 166 sells. Those positions are worth an estimated $6.8M at current prices.
Historically, Boulding Mark Elliott's trades have earned a middling insider score of 56/100 across 50 rated trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -12.1%.
The biggest single holding is PTCT (~$6.8M) as Executive VP and CLO. The recent filings there lean toward selling, a net 671,251 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 18, 2022 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE | 6,901 | $55.00 | $379,571.93 | -10.1% | -2.1% | -58.0% | |
| Sep 20, 2022 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE | 1,176 | $55.00 | $64,680.00 | -1.9% | -27.6% | -51.6% | |
| Apr 13, 2022 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE | 2,276 | $45.17 | $102,811.47 | -3.6% | -3.4% | +9.3% | |
| Apr 5, 2022 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE | 5 | $45.00 | $225.00 | - | +0.3% | +8.7% | |
| Feb 10, 2022 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE | 17,935 | $45.03 | $807,559.25 | -22.7% | -29.4% | +3.6% | |
| Feb 1, 2022 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sell | 779 | $40.00 | $31,161.56 | -1.3% | -10.7% | +16.9% | |
| Jan 7, 2022 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sell | 885 | $38.53 | $34,094.63 | -1.8% | +12.9% | +3.2% | |
| Sep 2, 2021 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE | 3,363 | $45.01 | $151,375.36 | -6.5% | -19.4% | +16.3% | |
| Jul 9, 2021 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE | 9,234 | $45.19 | $417,273.76 | -16.0% | -17.2% | +0.6% | |
| Feb 1, 2021 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sell | 778 | $56.96 | $44,311.77 | -1.6% | - | - |